Trials of intranasally administered rubella vaccine.
No evidence of vaccine virus transmission was found in two studies where Wistar RA 27/3 rubella vaccine was administered intranasally. Vaccine was immunogenic in all of 23 vaccinated children in one study, while in the other only 5 of the 11 vaccinees developed antibody. The reduced seroconversion rate in the latter study appears to have been caused by one or a combination of factors, including the vaccination technique, the presence of infective nasal conditions in vaccinees and the titre of vaccine used.
D000293:Adolescent; D000367:Age Factors; D000906:Antibodies; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D008722:Methods; D009666:Nose; D012411:Rubella Vaccine / Q000008:administration & dosage; D012412:Rubella virus; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage*
D000906:Antibodies; D012411:Rubella Vaccine; D014765:Viral Vaccines